Hlscience Co., Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Apr 2031
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Oct 7, 2027The maintenance fee for Method for alleviating osteoarthritis by using composite (HL-Joint 100) of achyranthes bidentata, eucommin ulmoides oliver and pomegranate extracts, which has antiinflammatory effect caused by COX2 and PGE2 inhibition, cartilage protective effect caused by MMP-2 and -9 inhibition and cartilage regeneration effect caused by increase in type II collagen synthesis (US 10,610,555) comes due Oct 7, 2027. Unpaid by Apr 7, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 6 of 6
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,986,749 | Pomegranate Extract Having a High Ellagic Acid Content, and Use of the Pomegranate Extract In force · High confidence | In force | High confidence | |
| US 9,901,536 | Composition for improving skin, containing pomegranate concentrate as active ingredient In force · From the USPTO record | In force | From the USPTO record | |
| US 10,709,750 | Female menopause alleviation use of composition containing composite extract of red clover and pomegranate as active ingredient In force · From the USPTO record | In force | From the USPTO record | |
| US 10,610,555 | Method for alleviating osteoarthritis by using composite (HL-Joint 100) of achyranthes bidentata, eucommin ulmoides oliver and pomegranate extracts, which has antiinflammatory effect caused by COX2 and PGE2 inhibition, cartilage protective effect caused by MMP-2 and -9 inhibition and cartilage regeneration effect caused by increase in type II collagen synthesis In force · From the USPTO record | In force | From the USPTO record | |
| US 10,155,019 | Method for improving gingivitis and periodontitis by antibacterial, antioxidant and anti-inflammatory effects and inhibition of alveolar bone loss of complex extracts of moringa leaf and eucommia bark In force · From the USPTO record | In force | From the USPTO record | |
| US 12,403,172 | Composition for preventing, alleviating or treating metabolic syndrome accompanied by obesity and/or diabetes, containing, as active ingredient, complex (IB complex) of Indian gooseberry extract and sprout barley extract In force · From the USPTO record | In force | From the USPTO record |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending